Rinvoq Warning Label Updated to Add Cancer and Heart Risks Seen With Xeljanz Side Effects
Cancer and heart risks linked to Rinvoq, Xeljanz and similar drugs have regulated them to secondary treatment options for rheumatoid arthritis.
Tag Archives: Incyte
-
-
Eli Lilly-Funded Study Claims Side Effects of Olumiant Do Not Warrant Same Adverse Label Warnings as Xeljanz
Study claims heart risks with Olumiant are the same as those of rheumatoid arthritis patients not taking the drug, raising questions about a class-wide warning after concerns about the side effects of Xeljanz emerged
-
Xeljanz Heart Risks May Be Similar Across Other JAK Inhibitors Like Rinvoq, Oluminant: Study
More research is needed into the link between Xeljanz and heart problems to determine how much of the risk is caused by side effects of the drugs, or the condition they are designed to treat, the researchers note
-
Opzelura Eczema Cream Investigation Announced Over Texture Problems
The issues come as similar drugs, like Xeljanz, face intense scrutiny over heart problems and cancer risks.
-
Xeljanz FDA Label Warning Update Adds Information About Risk of Cancer, Blood Clots and Heart Side Effects
-
Experts, FDA Concerned Xeljanz Heart and Cancer Problems May Affect Similar Arthritis Drugs
-
FDA Worried Jakafi May Have Cancer, Heart Risks Similar to Xeljanz
-
Jakafi Side Effects May Be Linked to PML Brain Disease: Report
